SOX2 and endometrial carcinoma: In addition to serving as a prognostic marker, whether SOX2 can assist EGFR and p53 as a predictive marker in gefitinib single treatment or combinatorial treatment with paclitaxel in endometrial carcinoma requires further investigation.